Regulatory T cells in cancer immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Control of Regulatory T Cell Development by the Transcription Factor Foxp3

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187

Regulatory T Cells and Immune Tolerance

Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,475

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer

Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090

N aturally A rising CD4+R egulatory T C ells for I mmunologic S elf -T olerance and N egative C ontrol of I mmune R esponses

Sakaguchi, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,315

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,906

Crosstalk between cancer‐associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290

Roles of the immune system in cancer: From tumor initiation to metastatic progression

Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976

Tumor microenvironment as a therapeutic target in cancer

Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 2,026

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, É., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,210

Regulatory T Cells and Human Disease

Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,163

T cells in health and disease

Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,153

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 972

Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis

Cai, J., Sun, L., & Gonzalez, F. J. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.004 · Cited by 892

Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment

Harjunpää, H., Asens, M. L., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 779

The future of cancer immunotherapy: microenvironment-targeting combinations

Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 768

Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer

Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 736

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591

Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion

Sawant, D. V., Yano, H., Chikina, M. D., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 569

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

Cheong, J. E., & Sun, L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 504

Targeting Treg cells in cancer immunotherapy

Tanaka, A., & Sakaguchi, S. (2019) · European Journal of Immunology · doi:10.1002/eji.201847659 · Cited by 484

Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity

Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218363 · Cited by 460

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation

Kaplanov, I., Carmi, Y., Kornetsky, R., Shemesh, A., Shurin, G. V., Shurin, M. R., Dinarello, C. A., Voronov, E., & Apte, R. N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812266115 · Cited by 457

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 431

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy

Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., Noguchi, T., Arthur, C. D., Meng, W., Alspach, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.030 · Cited by 422

Immune crosstalk in cancer progression and metastatic spread: a complex conversation

Garner, H., & de Visser, K. E. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0271-z · Cited by 405

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389

YAP and TAZ: a signalling hub of the tumour microenvironment

Zanconato, F., Cordenonsi, M., & Piccolo, S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0168-y · Cited by 388

UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma

Wolf, Y., Bartok, O., Patkar, S., Eli, G. B., Cohen, S., Litchfield, K., Levy, R., Jiménez-Sánchez, A., Trabish, S., Lee, J. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.032 · Cited by 382

Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer

Li, J., Wu, C., Hu, H., Qin, G., Wu, X., Bai, F., Zhang, J., Cai, Y., Huang, Y. J., Wang, C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.011 · Cited by 388

Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition

Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 368

Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy

Yang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 383

Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes

Elyahu, Y., Hekselman, I., Eizenberg-Magar, I., Berner, O., Strominger, I., Schiller, M., Mittal, K., Nemirovsky, A., Eremenko, E., Vital, A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw8330 · Cited by 324

T Cell Dysfunction in Cancer Immunity and Immunotherapy

Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 344

A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 336

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 329

Curcumin and colorectal cancer: An update and current perspective on this natural medicine

Weng, W., & Goel, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.011 · Cited by 287

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection

Urban‐Wójciuk, Z., Khan, M. M., Oyler, B. L., Fåhræus, R., Marek-Trzonkowska, N. M., Nita‐Lazar, A., Hupp, T. R., & Goodlett, D. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02388 · Cited by 314

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis

Lee, J., Mehdizadeh, S., Smith, J., Young, A., Mufazalov, I. A., Mowery, C. T., DAUD, A. I., & Bluestone, J. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba0759 · Cited by 321

Bacteria‐Based Cancer Immunotherapy

Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 306

Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells

Nair, V. S., & Elkord, E. (2017) · Immunology and Cell Biology · doi:10.1111/imcb.1003 · Cited by 304

Colorectal liver metastasis: molecular mechanism and interventional therapy

Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298

AP-1 Transcription Factors as Regulators of Immune Responses in Cancer

Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 295

Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution

Liu, Y., He, S., Wang, X., Peng, W., Chen, Q., Chi, D., Chen, J., Han, B., Lin, G., Li, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21043-4 · Cited by 297

The Unique Molecular and Cellular Microenvironment of Ovarian Cancer

Worzfeld, T., von Strandmann, E. P., Huber, M., Adhikary, T., Wagner, U. A. G., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 296

Antitumor effects of immunity-enhancing traditional Chinese medicine

Wang, Y., Zhang, Q., Chen, Y., Liang, C.-L., Liu, H., Qiu, F., & Dai, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109570 · Cited by 293

Nanomaterials for cancer immunotherapy

Song, W., Musetti, S., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 285

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer

Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275

Interleukin‐6/ STAT 3 signaling as a promising target to improve the efficacy of cancer immunotherapy

Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., Takahashi, N., & Taketomi, A. (2017) · Cancer Science · doi:10.1111/cas.13332 · Cited by 278

Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells

Liu, W., Zou, M., Liu, T., Zeng, J., Li, X., Yu, W., Li, C., Ye, J., Song, W. L., Feng, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11157-1 · Cited by 277

Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer

Wu, Q., Zhou, W., Yin, S., Zhou, Y., Chen, T., Qian, J., Su, R., Hong, L., Lu, H., Zhang, F., et al. (2019) · Hepatology · doi:10.1002/hep.30593 · Cited by 272

Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy

Song, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., Zhao, Y., He, Y., Tan, S., Guo, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03186 · Cited by 258

The dawn of vaccines for cancer prevention

Finn, O. J. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.140 · Cited by 257

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

Zhao, Y., Guo, S., Deng, J. M., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70958 · Cited by 265

Therapeutic targeting of regulatory T cells in cancer

Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.008 · Cited by 255

CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity

Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241

Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers

Lecarpentier, Y., Schussler, O., Hébert, J., & Vallée, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01248 · Cited by 251

Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation

Shalapour, S., & Karin, M. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.021 · Cited by 240

Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer

Li, D., Ji, H., Niu, X., Yin, L., Wang, Y., Gu, Y., Wang, J., Zhou, X., Zhang, H., & Zhang, Q. (2019) · Cancer Science · doi:10.1111/cas.14230 · Cited by 229

The multifaceted immune regulation of bladder cancer

Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 222

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

Yan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 226

Transgenic Mouse Models in Cancer Research

Tratar, U. L., Horvat, S., & Čemažar, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00268 · Cited by 231

Responsive biomaterials: optimizing control of cancer immunotherapy

Xue, L., Thatte, A. S., Mai, D., Haley, R. M., Gong, N., Han, X., Wang, K., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00617-2 · Cited by 219

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Xi, S., Lu, Y., & Fu, P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06119-x · Cited by 220

CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory

Kidani, Y., Nogami, W., Yasumizu, Y., Kawashima, A., Tanaka, A., Sonoda, Y., Tona, Y., Nashiki, K., Matsumoto, R., Hagiwara, M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114282119 · Cited by 212

Emerging role of PTEN loss in evasion of the immune response to tumours

Vidotto, T., Melo, C. M., Castelli, E. C., Koti, M., dos Reis, R. B., & Squire, J. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0834-6 · Cited by 211

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy

Wu, Y., Fang, Y., Qi, W., Shi, H., Tan, H., Deng, Y., Zeng, Z., Qiu, J., Chen, C., Sun, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214278119 · Cited by 209

Probiotic neoantigen delivery vectors for precision cancer immunotherapy

Redenti, A., Im, J., Redenti, B. J., Li, F., Rouanne, M., Sheng, Z., Sun, W. Y., Gurbatri, C. R., Huang, S., Komaranchath, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08033-4 · Cited by 216

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma

Oliveira, G., Stromhaug, K., Cieri, N., Iorgulescu, J. B., Klaeger, S., Wolff, J. O., Rachimi, S., Chea, V. A., Krause, K., Freeman, S. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04682-5 · Cited by 205

Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance

Wartenberg, M., Cibin, S., Zlobec, I., Vassella, E., Eppenberger‐Castori, S., Terracciano, L., Eichmann, M. D., Worni, M., Gloor, B., Perren, A. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3401 · Cited by 199

Metabolism in tumor microenvironment: Implications for cancer immunotherapy

Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 210

Cancer Vaccines, Adjuvants, and Delivery Systems

Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity

Whiteside, T. L. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1451514 · Cited by 203

Targeting CAFs to overcome anticancer therapeutic resistance

Saw, P. E., Chen, J., & Song, E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 206

Tregs: Where We Are and What Comes Next?

Hai, Z., Liao, X., & Kang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01578 · Cited by 200

Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology

Salomon, B. L., Leclerc, M., Tosello, J., Ronin, É., Piaggio, E., & Cohen, J. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00444 · Cited by 198

IRF4 instructs effector Treg differentiation and immune suppression in human cancer

Alvisi, G., Brummelman, J., Puccio, S., Mazza, E. M. C., Tomada, E. P., Losurdo, A., Zanon, V., Peano, C., Colombo, F., Scarpa, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130426 · Cited by 200

Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy

Wang, B., Tian, T., Kalland, K., Ke, X., & Qu, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.008 · Cited by 194

Adenosine signaling and the immune system: When a lot could be too much

Antonioli, L., Fornai, M., Blandizzi, C., Pacher, P., & Haskó, G. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.006 · Cited by 207

CAR-NK cells for cancer immunotherapy: from bench to bedside

Zhang, L., Yuan, M., Feng, X., & Han, Z. (2022) · Biomarker Research · doi:10.1186/s40364-022-00364-6 · Cited by 195

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 200

The Role of the Estrogen Pathway in the Tumor Microenvironment

Rothenberger, N. J., Somasundaram, A., & Stabile, L. P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020611 · Cited by 202

Correlate tumor mutation burden with immune signatures in human cancers

Wang, X., & Li, M. (2019) · BMC Immunology · doi:10.1186/s12865-018-0285-5 · Cited by 189

Tumor Abnormality-Oriented Nanomedicine Design

Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 203

Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy

Guerra, L., Bonetti, L., & Brenner, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107848 · Cited by 194

CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment

Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., Wang, Y., Yu, W., & Tao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722916 · Cited by 191

A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy

Shibata, M., Ham, K., & Hoque, M. O. (2018) · International Journal of Cancer · doi:10.1002/ijc.31561 · Cited by 190

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1445 · Cited by 186

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Xu, Y., Xiong, J., Sun, X., & Gao, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.001 · Cited by 188

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events

Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185

Blockade of Treg Cell Differentiation and Function by the Interleukin‐21–Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus

Kato, H., & Perl, A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40380 · Cited by 185

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181

Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer

Wang, L., Simons, D. L., Lu, X., Tu, T. Y., Solomon, S. T., Wang, R., Rosario, A., Avalos, C., Schmolze, D. B., Yim, J. H., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0429-7 · Cited by 174

Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses

Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S. E., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 175

Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment

Granito, A., Muratori, L., Lalanne, C., Quarneti, C., Ferri, S., Guidi, M., Lenzi, M., & Muratori, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2994 · Cited by 175

Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus

Dall’Era, M., Pauli, M. L., Remedios, K. A., Taravati, K., Sandova, P. M., Putnam, A. L., Lares, A., Haemel, A. K., Tang, Q., Hellerstein, M. K., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40737 · Cited by 173

RNA Nanotechnology-Mediated Cancer Immunotherapy

Lin, Y., Wang, Y., Blake, S., Yu, M., Mei, L., Wang, H., & Shi, J. (2019) · Theranostics · doi:10.7150/thno.35568 · Cited by 174

Immunomodulatory function and anti-tumor mechanism of natural polysaccharides: A review

Yang, Y., & Wu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147641 · Cited by 171

Immune Privilege and Eye-Derived T-Regulatory Cells

Keino, H., Horie, S., & Sugita, S. (2018) · Journal of Immunology Research · doi:10.1155/2018/1679197 · Cited by 165

Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells

Delacher, M., Simon, M., Sanderink, L., Hotz-Wagenblatt, A., Wuttke, M., Schambeck, K., Schmidleithner, L., Bittner, S., Pant, A., Ritter, U., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.007 · Cited by 164

Targeting Treg cells in cancer immunotherapy

Tanaka, A., & Sakaguchi, S. (2019) · European Journal of Immunology · doi:10.1002/eji.201847659 · Cited by 484

Targeting Regulatory T Cells for Cancer Immunotherapy

Fuerst, M. L. (2016) · Oncology Times · doi:10.1097/01.cot.0000508329.83580.01

Regulatory T cells in tumor immunity

Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 614

Abstract A058: Selective targeting of T regulatory cells by a TCR-mimic monoclonal antibody specific for foxp3-derived epitopes

Dao, T., Jarvis, C. A., Scott, A., Korontsvit, T., Zakhaleva, V., Pankov, D., Guerrerio, M. D. D. M., Mathias, M. D., Cheng, N. N., Liu, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-a058